Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1EO3G)

Drug Name
Odanacatib Drug Info
Synonyms MK 0822; MK0822; MK-0822A; Odanacatib (USAN)
Indication
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Phase 3 [1]
Cross-matching ID
PubChem CID
10152654
CAS Number
CAS 603139-19-1
TTD Drug ID
DM1EO3G
INTEDE Drug ID
DR1185

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Phase 1 [3]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Phase 1 [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cathepsin K (CTSK) DTT CTSK 7.502 8.157 6.955 8.046
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.791 3.744 3.413 1.609
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 15 Disease of the musculoskeletal system/connective tissue
Disease Class ICD-11: FA20 Rheumatoid arthritis
The Studied Tissue Bone marrow
The Studied Disease Osteoporosis [ICD-11:FA20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cathepsin K (CTSK) DTT CTSK 2.85E-01 -1.14 -2.61
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.23E-01 4.59E-02 6.37E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.60E-02 1.58E-01 1.36E+00
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01803607) Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076). U.S. National Institutes of Health.
2 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
3 Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos. 2014 May;42(5):818-27.